<DOC>
	<DOC>NCT00978315</DOC>
	<brief_summary>The study null hypothesis is that vitamin D supplementation will not influence time to upper respiratory tract infection or time to severe asthma exacerbation in adult and adolescent patients with asthma.</brief_summary>
	<brief_title>Trial of Vitamin D Supplementation in Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Principal Medical record diagnosis of asthma Age ≥ 16 years and ≤ 80 years on day of first dose of IMP If a woman of childbearing potential, is sexually abstinent or has negative pregnancy test within 7 days of recruitment and agrees to use reliable form of contraception until she has completed the study Able to give written informed consent to participate in the study Principal Diagnosis of COPD Known sarcoidosis, hyperparathyroidism, nephrolithiasis, active tuberculosis, vitamin D intolerance, liver failure, renal failure, terminal illness, lymphoma or other malignancy not in remission for ≥ 3 years Any other condition that, in an investigator's judgement, might compromise patient safety or compliance, interfere with evaluation or preclude completion of the study Taking benzothiadiazine derivative, cardiac glycoside, carbamazepine, phenobarbital, phenytoin or primidone Taking dietary supplement containing vitamin D up to 2 months before first dose of IMP Treatment with any investigational medical product or device up to 4 months before first dose of IMP Breastfeeding, pregnant or planning a pregnancy Baseline corrected serum calcium &gt; 2.65 mmol/L Baseline serum creatinine &gt; 125 micromol/L Smoking history &gt;15 packyears</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>